Wuhan YZY Biopharma Co Ltd (HKSE:02496) Share Price

Company Profile

Business description
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer, and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas. The company has designed and developed various clinical-stage candidate drug pipelines, such as M701 (EpCAM CD3 bispecific antibody), Y101D, Y150, Y2019 (RBD dimer subunit SARS-CoV-2 vaccine), M802, and Y400 (VEGFxANG2 bispecific antibody) for the treatment of different cancer and age-related complications. Geographically, the company derives all of its revenue from the People's Republic of China (PRC).
Contact
No. 666 Gaoxin Road
Building C2-1, Guanggu Biocity
East Lake High Tech Development Zone
Hubei Province
Wuhan
CHN
T: +86 2782668988
http://www.yzybio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
106

Recommended

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.

Malik Ahmed Khan, CFA | 05 September 2025

A difficult year but better times ahead.

Johannes Faul, CFA | 05 September 2025

Find out how this defensive player has fared after earnings.

Simonelle Mody | 03 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,140.50	11.00	0.12%
CAC 40	7,674.78	24.14	-0.31%
DAX 40	23,596.98	173.35	-0.73%
Dow JONES (US)	45,400.86	220.43	-0.48%
FTSE 100	9,208.21	8.66	-0.09%
HKSE	25,417.98	359.47	1.43%
NASDAQ	21,700.39	7.30	-0.03%
Nikkei 225	43,018.75	438.48	1.03%
NZX 50 Index	13,223.53	90.33	0.69%
S&P 500	6,481.50	20.58	-0.32%
S&P/ASX 200	8,871.20	8.60	0.10%
SSE Composite Index	3,812.51	46.64	1.24%